Wesley Nolte @Wesl3y: "𝗠𝗮𝗿𝗸𝗲𝘁 𝗨𝗽𝗱𝗮𝘁𝗲 𝟮𝟮 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟲 𝘾𝙚𝙖𝙨𝙚𝙛𝙞𝙧𝙚..."

United Kingdom

𝗠𝗮𝗿𝗸𝗲𝘁 𝗨𝗽𝗱𝗮𝘁𝗲 𝟮𝟮 𝗔𝗽𝗿𝗶𝗹 𝟮𝟬𝟮𝟲 𝘾𝙚𝙖𝙨𝙚𝙛𝙞𝙧𝙚 𝙚𝙭𝙩𝙚𝙣𝙙𝙚𝙙, 𝙗𝙪𝙩 𝙝𝙚𝙡𝙙 𝙩𝙤𝙜𝙚𝙩𝙝𝙚𝙧 𝙬𝙞𝙩𝙝 𝙩𝙖𝙥𝙚 Trump extended the ceasefire yesterday. The first round of talks obviously collapsed. A second round was expected this week, but Iran hasn't confirmed, and the US naval blockade of Iranian ports continues. The Strait is still a trickle, and Iran is calling the blockade "an act of war." Oil has backed off from its peak. Meaningful relief, but definitely not the "all clear." Any breakdown in talks and oil spikes again. 𝙏𝙝𝙚 𝙑-𝙨𝙝𝙖𝙥𝙚 𝙞𝙨 𝙧𝙚𝙖𝙡 The $SPX500 and $NSDQ100 both hit fresh all-time highs, fully recovering from the war-driven selloff. The Nasdaq ran a 13-session winning streak into Monday, its longest in over a decade. Both have eased on renewed nerves around the ceasefire deadline. That said, not everything has come back. Software stocks, double-punched first by AI-disrupting-SaaS fears and then by the oil beat-down, are still well off their highs. $NOW (ServiceNow Inc) is down ~35% YTD, and many other quality SaaS names are down double-digits. That's where the opportunity still sits. 𝙋𝙤𝙧𝙩𝙛𝙤𝙡𝙞𝙤 𝙢𝙤𝙫𝙚𝙨 I've added more $MSFT (Microsoft) and a starter position on $NOW: * MSFT: the clearest beneficiary of enterprise AI adoption. Dominant cloud, Copilot pricing power, and a balance sheet that lets them outspend almost anyone. * NOW: the workflow backbone for large enterprises. Bears argue AI agents eat orchestration, but enterprise workflows are sticky, customised, and wired into every system of record. My 25+ years as a tech consultant tell me AI is not a replacement but a tool in their belt. 𝙊𝙪𝙩𝙡𝙤𝙤𝙠 We're in this for the long run. The combination of AI-SaaS fears, followed by the oil shock beat down some fantastic businesses. That sets up well for patient investors willing to hold through the noise. Markets have reminded us once again that the damage from geopolitical shocks is usually shorter than the headlines suggest. Stay invested. Stay diversified. Stay patient.

Not investment advice. The author may have financial interests in the mentioned instruments.